CA
ALNY icon

Crewe Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Crewe Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$178 – 421
2023
Q3 		$178 Hold
1
– – ﹤0.01% 453
2023
Q2 		$190 Sell
1
-26
-96% -$5.16K ﹤0.01% 723
2023
Q1 		$5.41K Sell
27
-23
-46% -$4.83K ﹤0.01% 626
2022
Q4 		$11.9K Sell
50
-36
-42% -$7.68K ﹤0.01% 522
2022
Q3 		$17K Buy
86
+15
+21% +$2.86K ﹤0.01% 498
2022
Q2 		$10K Buy
+71
New +$10.1K ﹤0.01% 587

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Crewe Advisors's ALNY Position: Q4 2023 in Review

Crewe Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1 share — an estimated $178 sold.

Crewe Advisors first reported a position in ALNY in Q2 2022 and held it in 6 quarters. The position peaked at $17K in Q3 2022. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Crewe Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Crewe Advisors sold 1 Alnylam Pharmaceuticals share in Q4 2023, an estimated $178.
  • Crewe Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Crewe Advisors's Alnylam Pharmaceuticals position peaked at $17K in Q3 2022.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.